Sermorelin

Both are GHRH analogues that stimulate pituitary GH release, but their pharmacokinetic profiles differ meaningfully. Sermorelin (GHRH 1-29) has a short half-life — approximately 10 to 20 minutes — requiring daily injection and producing a more acute pulsatile GH stimulus. CJC-1295 with DAC has been chemically modified to extend its half-life to several days, allowing less frequent (typically twice weekly) dosing and producing more sustained GH elevation. Sermorelin's shorter action profile more closely mirrors natural GHRH physiology; CJC-1295 provides more sustained coverage. Clinical choice depends on patient preference for dosing frequency, cost, compounding availability, and individual response. Sermorelin is generally the more established and conservatively documented option.

Sermorelin was previously FDA-approved as Geref Diagnostic for evaluating growth hormone deficiency in children, and a therapeutic form (Gerel) was approved for pediatric GH deficiency treatment. Both products were voluntarily withdrawn from the US market for commercial reasons unrelated to safety. Sermorelin is not currently FDA-approved for any indication including adult growth hormone support. Adult use is off-label, available through compounding pharmacies under applicable regulations. SPOKEmed discusses regulatory status transparently with patients before any sermorelin prescription.

Sermorelin has not been placed on the FDA's difficult-to-compound Category 2 list as of recent guidance, which means it has been more continuously available through US compounding pharmacies than some other GHRPs. However, compounding availability for any peptide can change based on FDA guidance updates, DEA scheduling changes, or state pharmacy board regulations. SPOKEmed verifies current compounding availability before prescribing sermorelin and communicates any changes to patients in real time.